DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

计划入组 450 人 · 首次发布于 2025 年 5 月 1 日

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

计划入组 862 人 · 首次发布于 2023 年 6 月 22 日

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

计划入组 594 人 · 首次发布于 2025 年 3 月 24 日

DB-1311

AL-1311

JLP-1311

Renovaro

United States

AUREALIS OY

Finland

Espero Pharmaceuticals, Inc.

United States

BNT324/DB-1311 Shows Promise in Advanced Solid Tumors: ESMO Asia 2024

Novel B7H3 Antibody-Drug Conjugate Shows Strong Efficacy in Cervical and Ovarian Cancers

DualityBio Achieves Phase 3 Success with Lead ADC Candidate, Advances Global Pipeline Across Multiple Cancer Types